This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Intuitive Surgical Gains From Solid Q2 and Strong AI Exposure
by Zacks Equity Research
Intuitive Surgical's (ISRG) impressive second-quarter 2018, strength in robotics and AI trends buoy optimism.
Hologic Launches Fluent Fluid Management System, Widens Suite
by Zacks Equity Research
Hologic (HOLX) adopts initiatives to boost the GYN Surgical segment.
Here's Why You Should Invest in Align Technology (ALGN) Now
by Zacks Equity Research
We are upbeat about Align Technology's (ALGN) solid Invisalign Technology prospects and growth in North America and internationally.
AngioDynamics' (ANGO) BioSentry Buyout to Boost Oncology
by Zacks Equity Research
AngioDynamics' (ANGO) latest buyout to bolster its core Oncology unit; market prospects look bright.
Wright Medical Strong Overseas, Back Order Issues Persist
by Zacks Equity Research
Wright Medical (WMGI) rides on recent approval of AUGMENT Injectable and a solid guidance for 2018; pricing pressure prevails.
Medtronic Launches IN.PACT Admiral in Japan, Boosts APV Arm
by Zacks Equity Research
Medtronic's (MDT) recent launch of IN.PACT Admiral DCB in Japan is expected to boost the top line.
Masimo's SET Pulse Oximetry Detects Sleep Apnea in Children
by Zacks Equity Research
Masimo's (MASI) SET pulse oximetry successfully identifies DS in children with high risk of OSA.
Inogen's Solid Europe Business Shapes Q2, Prospects Bright
by Zacks Equity Research
Inogen's (INGN) Europe performance solid in Q2; guidance for 2018 encourages.
Bio-Rad (BIO) Banks on Blood Typing Market Amid Margin Woes
by Zacks Equity Research
Bio-Rad (BIO) actively expands portfolio for blood typing market; declining gross margin a concern.
Becton, Dickinson Global Foothold Strong, Recalls Rampant
by Zacks Equity Research
Becton, Dickinson (BDX) gains from solid global foothold in Q3; foreign exchange headwinds raise concern.
Has Intuitive Surgical (ISRG) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (ISRG) Outperforming Other Medical Stocks This Year?
STERIS (STE) Q1 Earnings & Revenues Beat Estimates, Up Y/Y
by Zacks Equity Research
STERIS (STE) continues to gain from strength in all business segments in Q1.
Allscripts Sunrise Picked by UK's Maidstone and Tunbridge Wells
by Zacks Equity Research
Allscripts' (MDRX) Sunrise platform witnesses a suite of developments, fortifying the company's global foothold.
Haemonetics (HAE) Q1 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Haemonetics' (HAE) year-over-year growth is backed by the solid execution of its multi-year turnaround strategy.
OPKO Health (OPK) Earnings & Revenues Beat Estimates in Q2
by Zacks Equity Research
OPKO Health (OPK) gains from robust demand for its flagship RAYALDEE; declining segmental revenues raise concern.
Wright Medical (WMGI) Beats on Q2 Earnings, Raises '18 View
by Zacks Equity Research
Growth in the upper and lower extremity segments drives Wright Medical's (WMGI) Q2 results.
Bio-Rad (BIO) Tops Earnings and Revenue Estimates in Q2
by Zacks Equity Research
Bio-Rad's (BIO) solid growth in North America, China and Asia Pacific reflects strong international foothold in Q2.
CVS Health's (CVS) Q2 Earnings Beat Estimate, Margins Up
by Zacks Equity Research
CVS Health (CVS) reports strong Pharmacy Services revenues, benefiting from the upside in the specialty services. Year-over-year Retail/LTC comparisons are also encouraging.
BioScrip (BIOS) Q2 Loss Wider Than Expected, Revenues Top
by Zacks Equity Research
A shift in BioScrip's (BIOS) strategy and the impact of implementing ASC 606 induce a Q2 earnings miss for the company. However, its progress with the new multi-faceted CORE plan is a positive.
Allscripts Gains From Strong Results in Q2, Competition Rife
by Zacks Equity Research
Allscripts (MDRX) continues to gain from solid Q2 results and EHR developments; a competitive industry is a concern.
Penumbra (PEN) Q2 Earnings & Revenues Top Estimates, View Up
by Zacks Equity Research
Penumbra (PEN) benefits from strong growth across all geographies and product lines in Q2.
Inogen (INGN) Beats on Q2 Earnings, Lifts '18 Sales Guidance
by Zacks Equity Research
Inogen (INGN) puts up solid segmental show in Q2; international sales surge.
Surmodics (SRDX) Beats Q3 Earnings Estimates, Raises '18 View
by Zacks Equity Research
Surmodics' (SRDX) third-quarter fiscal 2018 results benefit from increase in royalty and license fee revenues.
Teleflex (TFX) Q2 Earnings Top, Sales Lag, '18 View Bearish
by Zacks Equity Research
Teleflex (TFX) rides high on a strong year-over-year revenue improvement, banking on balanced segmental growth and wide geographical expansion.
DENTSPLY (XRAY) Beats on Q2 Earnings, Lowers 2018 Guidance
by Zacks Equity Research
DENTSPLY (XRAY) gains from solid year-over-year international revenue growth in Q2; high impairment charges in the quarter mars results.